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Abstract
Background: Hepatocellular carcinoma (HCC) is associated with inflammation, and roughly 30 % of the global
population shows serological evidence of current or past infection with hepatitis B or hepatitis C virus. Resident
hepatic macrophages, known as Kupffer cells (KCs), are considered as the specific tumor-associated macrophages
(TAMs) of HCC, and can produce various cytokines—most importantly interleukin (IL)-6—to promote tumorigenesis
of HCC. However, the roles of KCs and IL-6 in carcinogenesis in the liver are still unclear.
Methods: We analyzed leukocyte-related peripheral blood data of 192 patients and constructed a mouse model in
which the bone marrow was cleared out by irradiation and reconstructed using bone marrow donated from IL-6-
deficient mice to further elucidate the hepatic pathological changes in response to toxic challenge and oncogenic
gene mutation.
Results: Peripheral monocyte counts and serum IL-6 levels were significantly higher in patients with HCC than in
those without HCC. In addition, there was a significant difference in the levels of IL-6 among individuals with
different histopathological grades. In mice with selective IL-6 ablation in monocytes/KCs, we observed decreased
toxic liver injury, inflammatory infiltration, and systemic inflammation. In Mdr2-deficient mice, which spontaneously
developed HCC, the loss of IL-6 in monocytes/KCs resulted in inhibition of IL-6/signal transducer and activator of
transcription 3 signaling, decreased serum IL-6 levels, and delayed tumorigenesis.
Conclusions: Our findings demonstrate that increased TAM-derived IL-6 had an amplifying effect on the
inflammation response, thereby promoting the occurrence and development of HCC.
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Background
Hepatocellular carcinoma (HCC) is the most common
type of primary tumor of the liver, representing approxi-
mately 85–90 % of primary hepatic malignancies. HCC
is ranked the fifth and seventh most common cancer in
men and women, respectively, and represents the third
leading cause of neoplasm-related death worldwide [1].
Since the first documented proposition of an associ-
ation between inflammation and cancer by the German
pathologist Rudolf Virchow Chronic in the mid-19th
century, our understanding of inflammation and cancer
has improved dramatically [2]. Immune activation and
persistent inflammation have been shown to contribute
to malignancy, and local chronic tissue inflammation
often leads to malignant transformation [3, 4]. Further-
more, a randomized clinical trial showed that patients
receiving long-term therapy (>5 years) with anti-
inflammatory drugs, such as aspirin, had fewer relapses
or appearances of new tumors, particularly colon cancer,
providing further evidence for the pro-cancer effects of
long-term inflammation [5]. HCC has been shown to be
associated with chronic viral infection, such as hepatitis
B virus (HBV) and hepatitis c virus (HCV) [6, 7], and is
thought to be driven by inflammation. Moreover,
roughly 30 % of the world’s population shows serological
evidence of current or past HBV or HCV infection, with
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particularly high infection rates in China [8]; Thus, elu-
cidation of the relationship between HCC and inflamma-
tion is critical for the development of improved
therapies to manage HCC.
Monocytes are an important type of leukocytes and
can differentiate into macrophages. Within the tumor
microenvironment, macrophages can further differenti-
ate into TAMs. TAMs are the main population of in-
flammatory cells in solid tumors and release cytokines
that contribute to the occurrence and development of
tumors [9]. Additionally, macrophages have both anti-
and pro-cancer activities through the expression of dif-
ferent functional programs in response to distinct micro-
environmental signals [10]. KCs, the resident hepatic
macrophages, are considered HCC-specific TAMs. KCs
make up less than 5 % of the volume of the liver; how-
ever, they represent about 80 % of the total fixed macro-
phage population in the human body [11]. Owing to
their wide range of biological functions in immune regu-
lation, inflammation, and oncogenesis, KCs are involved
in the pathogenesis of several liver diseases. As a basic
protective function and the first line of defense in the
healthy liver, KCs exert immune functions through
phagocytosis and antigen presentation for components
entering from the portal vein and arterial circulation.
However, the initial activation of KCs can cause liver in-
jury and hepatocyte cell death through the release of
inflammatory cytokines and production of matrix metal-
loproteinases (MMPs), thereby contributing to later
stages of wound healing and fibrosis regression and
eventually leading to liver cirrhosis [12]. The develop-
ment of HCC occurs in about one-third of individuals
with cirrhosis and is closely related to KCs. Based on
phenotypic polarization, the state of activation of KCs
can be classified as M1 (classically activated) or M2
(alternatively activated) [13]. Within the tumor micro-
environment, TAMs are mainly polarized towards the
M2 phenotype [14]. Although the specific mechanism is
still unclear, macrophage polarization is strongly related
to tumor stage, suggesting that dynamic switching from
the M1 phenotype during the early phases of chronic
inflammation to an M2-like phenotype may occur in
established tumors [15].
IL-6 is a pleiotropic cytokine that is mainly produced
by macrophages and lymphocytes [16]. IL-6 is one of the
key factors involved in the inflammatory response asso-
ciated with the course of hepatitis due to hepatitis virus-
related infection [17, 18]. In the inflammatory response,
IL-6 acts as an activator by controlling the hepatic acute
phase (AP) response [19], which is critical for the main-
tenance of body homeostasis during infections and
inflammatory conditions after trauma, burns, tissue ne-
crosis, and surgery [20]. IL-6 can activate several path-
ways, including the Janus kinase (JAK)/signal transducer
and activator of transcription (STAT), p38 mitogen-
activated protein kinase (MAPK), extracellular signal-
regulated kinase (ERK), and phosphoinositol 3-kinase
(PI3K) pathways, ultimately leading to cell proliferation,
protection from apoptosis, and increased metastatic po-
tential [18]. Of these signaling pathways, the JAK/STAT
pathway is one of the most important in mediating the
inflammatory response. In this pathway, IL-6 family
members interact with a receptor complex on the cell
surface. IL-6 first binds to the IL-6 receptor (glycopro-
tein (gp) 80) and then interacts with gp130. Subse-
quently, dimerization of two gp130 molecules activates
JAKs, which phosphorylate specific tyrosine residues of
gp130 and thus activate the transcription factors STAT3
and other potential pathways, resulting in the activation
of the AP response [21]. STAT3 was initially described
as a DNA-binding factor expressed in TAM-derived IL-
6-stimulated hepatocytes and has been shown to be cap-
able of selectively interacting with an enhancer element
in the promoter of AP genes, known as AP response ele-
ments [22]. In rodents, IL-6 is a progrowth factor re-
quired for hepatic regeneration and survival after partial
hepatectomy [23, 24]. In mice, Streetz et al. suggested
that IL-6 has a protective role in non-parenchymal liver
cells during fibrosis progression in the pathogenesis of
chronic liver diseases [25]. Moreover, in humans,
Wieckowska et al. reported that IL-6 expression is mark-
edly higher in the livers of patients with nonalcoholic
steatohepatitis (NASH) than in patients with simple
steatosis or normal biopsies [26]. Additionally, IL-6
expression in hepatocytes is positively correlated with
the degree of inflammation and stage of fibrosis in these
patients [26]. Many clinical studies have also shown that
IL-6 expression is increased in HCC [27, 28]. Taken to-
gether, these findings support that the role of IL-6 in
liver disease varies greatly between humans and animals,
and the direct relationships between IL-6 and HCC are
still unclear.
Although many studies have demonstrated that HCC
is closely correlated with aberrant IL-6 expression, the
direct relationships between TAM-derived IL-6 and
HCC are still not clear. In order to explore the role of
TAM-derived IL-6 in the occurrence and development
of HCC, the most important initial step is to establish a
suitable model. Currently, there are three models that
may be consistent with our experimental objective; these
include gadolinium chloride (GdCl3)-induced, systemic
IL-6-knockout, and conditional gp130-knockout (Cre/
loxP system) murine models. However, all of these
models are associated with large biases, which may re-
sult in unreliable results.
Therefore, to investigate the central role of TAM-
derived IL-6 in the occurrence and development of
HCC, we developed a monocyte-selective IL-6-deficient
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mouse model using mice in which the bone marrow was
deconstructed and then reconstituted with bone marrow
donated from a systemic IL-6-deficient mouse. We eluci-
dated the occurrence and development of liver cancer in
response to toxin challenge and mdr2 gene ablation in
the monocyte-specific IL-6-deficient mice.
Methods
Patients
A total of 192 patients (HCC = 113 and Non-HCC = 59)
from Jun.1, 2015 to Feb.1 2016 in our center were in-
cluded in this study. The Non-HCC group consists of
the donors of living donor liver transplantation (n = 10),
patients with hepatic hemangioma (n = 19) or chronic
liver disease (n = 30). All of the data of HCC patients
come from the patients who are undergoing liver resec-
tion (HR) or liver transplantation (LT), and diagnosis
was confirmed by histopathologic examination of the
surgical samples. To ensure the consistency of baseline
data, all patients are diagnosed with HCC for the first
time, and with non-liver infectious diseases such as urin-
ary, respiratory or other system inflammation.
Mice and treatment
(B6 × 129) F2 (B6.129) mice homozygous for IL-6 muta-
tion was donated by Dr. Yu, West China Hospital,
Sichuan University. We chose the mdr2−/− mice as a
spontaneous tumor model which highly mimics the
inflammation-associated HCC [29]. The mice were
maintained on an alternating 12-h light/dark cycle, fed
regular chow, and given water ad libitum.
Bone marrow transplantation
Four to ten weeks old IL-6−/− or littermate mice were
used as bone marrow (BM) donors and the BM cells
were isolated from their femur, tibia, and humerus. Ten-
week old recipient Balb/c mice fed with medicated water
one week before irradiation. To ablation the BM, mice
were exposed to a dose of 8 Gy γ-irradiation. Then the
mice were transplanted with 106 BM cells via tail vein
within six hours following ion exposure. The experimen-
tal design is illustrated in Fig. 2a.
Histological staining
Liver tissues were fixed in 10 % formaldehyde and
the 4-μm sections were subjected to hematoxylin and
eosin staining. For immunohistochemistry staining,
paraffin-embedded liver sections were incubated with
appropriately diluted antibodies. The results were de-
veloped by the 3,3’-diaminobenzidine (DAB) method.
Mouse monocyte isolation
Mouse blood was collected and added into EDTA vacu-
tainer tubes. Erythrocytes were lysed using red blood cell
(RBC) lysis solution for 5 min at room temperature.
Cells were centrifuged at 1000 g for 3 min to remove
RBC lysis solution, and the leukocyte pellet was resus-
pended and washed with phosphate-buffered saline
(PBS). Cell viability was counted by trypan blue
exclusion.
mRNA isolation and real-time RT-PCR
Total mRNA was purified from isolated circulating
monocytes with Trizolreagent (Invitrogen, United
States). mRNA was reverse transcribed to cDNA using
an iScript cDNA Synthesis kit (Bio-Rad, United States).
Q-PCR reactions were performed using a Bio-Rad
CFX96TM Real-Time PCR system with SsoFastTM Eva-
Green Supermix (Bio-Rad). The relative expression of
target genes was normalized to an internal β-actin con-
trol. Relative gene expression with a greater than 2-fold
change was considered statistically significant. The se-
quences of mouse IL-6 gene primers were: upstream, 5’-
CAC GGC CTT CCC TAC TTC ACATG AGG ACA
CTT GCC TGG TG-3’, and downstream, 5’-TTC TGC
AAG TGC ATC ATC GT-3’.
Cytokine level analysis
Serum cytokine levels were analyzed on a Luminex 200
system using a Millipore Map Mouse Cytokine/Chemo-
kine Magnetic Bead Panel kit (Millipore, United States)
according to the manufacturer’s instructions.
Western blot analysis
The livers were homogenized for protein extraction. So-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and immunoblotting were performed and an
ECL reagent was used for chemiluminescence detection.
Statistical analysis
All results were expressed as the mean ± SD. SPSS 18.0
statistical software (SPSS Inc., Chicago, IL, USA) and
GraphPad Prism 5 software were used to analyse the rele-
vant data. For statistical analysis, Categorical data were
presented as number (per cent) and compared using Pear-
son chi-Square, Fisher’s exact test. Continuous variables
were expressed as the mean value ± SD and analysed using
t-test. P < 0.05 was considered statistically significant.
Results
Clinical data for patients with and without HCC
In our clinical retrospective observation, a total of 155
cases were selected (with HCC, n = 113; without HCC,
n = 59). The baseline characteristics and disease features
of patients with and without HCC and patients with
HCC classified as histopathological grades I, II, and III
were summarized in Table 1. There were no significant
differences between patients with and without HCC and
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among patients with grades I, II, or III HCC in terms of
baseline demographics and disease features. Moreover,
there were no significant differences in the numbers of
lymphocytes in patients with or without HCC (1.48 ±
0.52 × 109/L versus 1.47 ± 0.54 × 109/L, respectively; P =
0.926; Fig. 1b). In contrast, the counts of peripheral neu-
trophils, monocytes, leukocytes, and serum IL-6 levels
were significant higher in patients with HCC than in pa-
tients without HCC (Fig. 1a, c-e). In addition, there was
a significant difference in IL-6 expression among indi-
viduals with different histopathological grades (Fig. 1f ).
Construction of monocyte-specific IL-6-deficient mice
Ion irradiation at 8 Gy completely cleared out the BM in
all recipient mice (Fig. 2b), and mice died within 7 days
if BM transplantation was not performed. BM was
reconstituted after the infusion of BM donated by either
IL-6−/− or WT donors (Fig. 2b). Mice that survived for
more than 1 month after BM transplantation were con-
sidered to have undergone successful BM reconstitution
and were used for further experiments.
To confirm IL-6 disruption in monocytes, we activated
circulating monocytes by intraperitoneal injection of
lipopolysaccharide (LPS) at 1 μg/kg bodyweight (BW)
and isolated monocytes from the blood 60 min later. We
performed quantitative polymerase chain reaction (PCR)
to quantify IL-6 mRNA transcription in circulating
monocytes. The results showed that IL-6 mRNA levels
in the mice receiving IL-6 deficient BM were substan-
tially decreased (Fig. 2c).
Table 1 Baseline demographic and disease features characteristics
Variables HCC Non-HCC P value Grades I Grades II, III P value
(n = 113) (n = 59) (n = 39) (n = 74)
Age (mean ± SD,years) 53.66 ± 11.52 51.52 ± 11.63 0.250 55.44 ± 12.28 53.37 ± 11.81 0.405
Male (%) 90 (79.6 %) 44 (74.6 %) 0.447 29 (80.6 %) 55 (82.1 %) 0.848
Height (mean ± SD, cm) 164.64 ± 6.36 164.80 ± 3.80 0.833 163.25 ± 7.11 165.33 ± 6.34 0.131
Weight (mean ± SD, kg) 63.17 ± 10.33 61.69 ± 5.68 0.227 62.38 ± 10.22 63.77 ± 11.18 0.539
BMI (mean ± SD, kg/m2) 23.25 ± 3.17 22.68 ± 1.60 0.123 23.36 ± 3.25 23.25 ± 3.37 0.875
HBV positivity (%) 82 (72.6 %) 38 (64.4 %) 0.269 26 (72.2 %) 50 (74.6) 0.791
Number of tumors (>1,%) - - - 9 (23.1 %) 18 (24.3 %) 0.882
Largest tumor size (mean ± SD, cm) - - - 4.83 ± 2.77 4.68 ± 1.98 0.743
BMI Body mass index, HBV hepatitis B virus
Fig. 1 Peripheral blood data for patients. a-e The counts of neutrophils, lymphocytes, monocytes, total leukocytes in the blood and serum levels
of IL-6 in the HCC (n = 113) and Non-HCC group (n = 59) (3.57 ± 1.38 vs. 2.62 ± 0.93, 109/L, P < 0.001; 1.48 ± 0.52 vs. 1.47 ± 0.54, 109/L, P = 0.926;
0.45 ± 0.16 vs. 0.35 ± 0.13, 109/L, P < 0.001; 5.71 ± 1.67 vs. 4.96 ± 1.20, 109/L, P = 0.003; 8.75 ± 13.13 vs. 2.66 ± 2.36, pg/ml, P = 0.001 respectively) (f)
Serum IL-6 level in the histopathologic gradesIgroup (n = 39) and gradesII, III group (n = 74) (14.02 ± 15.95 vs. 5.98 ± 10.46, pg/ml, P = 0.006)
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IL-6 deprivation in monocytes decreased toxic liver injury
Hepatic macrophages, derived either from the renewal
of resident KCs or from recruitment of circulating
monocytes, play critical roles in initiation and exacerba-
tion of acute liver damage in response to toxin challenge
[12]. Thus, we next treated WT mice with irradiation
and reconstituted the BM by donation of BM from IL-6-
deficient or WT mice (described as Wt/IL6−/− and Wt/
IL6+/+ mice, respectively). After successful BM reconsti-
tution, the mice were intraperitoneally injected with
10 % carbon tetrachloride (CCl4) solution in olive oil at
10 mL/kg body weight (BW). Liver specimens and blood
samples were harvested on days 1 and 2 after toxin
injection. Wt/IL6+/+ mice showed severe liver damage
and their hepatic indexes, including alanine aminotrans-
ferase (ALT) and glutamic-oxalacetic transaminase
(AST), were dramatically increased on day 1, with fur-
ther deterioration observed on day 2. In contrast, in Wt/
IL6−/− mice, liver histology was well maintained, and
hepatic indexes were mildly to moderately increased
(Fig. 3a, b).
Next, we examined the infiltration of macrophages in
the liver. As illustrated by F4/80 immunoreactivity, in
WT/IL6+/+ mice, macrophages were aggregated around
the necrotic parenchyma, whereas fewer F4/80-positive
cells were observed in WT/IL6−/− mice (Fig. 3c, d).
Acute hepatic damage is often accompanied with a sys-
temic inflammatory response. Therefore, we examined the
levels of circulating factors, including IL-6, tumor necrosis
factor (TNF)-α, interferon (INF)-γ, and IL-1α. As ex-
pected, all of these factors were significantly upregulated
in WT/IL6+/+ mice as compared with their levels in WT/
IL6−/− mice (Fig. 3e).
Inflammatory infiltration and systemic inflammation were
reduced in IL-6-deficient mice
Mdr2-deficient mice lack the ability to secrete phospho-
lipid into the bile from hepatocytes and develop spontan-
eous chronic non-suppurative inflammatory cholangitis
with portal inflammation and ductular proliferation [29].
We next replaced the BM of Mdr2−/− mice with IL-6-
deficient BM (described as Mdr2−/−/IL6−/− and Mdr2
−/−/IL6+/+ mice, respectively) and then examined inflam-
matory infiltration in the liver at 2 months of age. In
Mdr2−/−IL6+/+ mice, liver histology was noticeably im-
paired, and obvious inflammatory cell infiltration was ob-
served in the parenchyma (Fig. 4a). Although hepatocyte
injury was also prominent in Mdr2−/−/IL-6−/− mice, the
numbers of infiltrated inflammatory cells and F4/80-posi-
tive cells were greatly lower in livers from these mice than
in livers fromMdr2−/−/IL6+/+ mice (Fig. 4a).
We then measured the levels of circulating cyto-
kines in mice of both genotypes. As expected, all cy-
tokines examined in this study were substantially
increased in Mdr2−/−IL6+/+ mice and moderately
Fig. 2 Reconstitution of the bone marrow with IL-6 deficient donors. a Schematic representation of the experimental design. b Histology examination
of the deconstruction and reconstruction of the bone marrow. c The transcription levels of IL-6 mRNA in circulating monocytes. Each bar represents
the mean ± s.e.m from ≥3 independent quantitative PCR experiments. Gaphd was used as loading control.***p < 0.001
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elevated in Mdr2−/−IL6−/− mice as compared with
those in WT mice (Fig. 4b).
IL-6-deficient mice exhibited a lower rate of spontaneous
liver cancer than WT mice
Because Mdr2 ablation leads to early spontaneous car-
cinogenesis at 4–6 months of age [29], we examined the
development of liver cancer at 6 months of age in IL-6-
deficient and WT mice. All 12 Mdr2−/−IL-6+/+ mice and
four of 13 Mdr2−/−IL6−/− mice developed liver cancer.
Moreover, the mean tumor size was much smaller in
Mdr2−/−IL6−/− mice than inMdr2−/−IL6+/+ mice (Fig. 5a).
A comparison of the ratio of liver weight (LW) to BW
showed that LW/BW was much lower in Mdr2−/−IL6−/−
mice than in Mdr2−/−IL-6+/+ mice (Fig. 5b).
Next, we examined the expansion of macrophages in
the liver. The infiltration of F4/80-positive cells was rare
in Mdr2−/−IL6−/− mice. However, noticeable aggregation
of macrophages was observed in Mdr2−/−IL-6+/+ mice
(Fig. 5c).
Fig. 3 IL-6 deprivation in monocytes decreases toxic liver injury. a-b Specific loss of IL-6 in monocytes improves liver histology and decreases
toxic liver injury. c-d Less macrophage aggregation in liver tissue when their IL-6 was deprived. The numbers of F4/80-positive cells were counted
in 10 consecutive high-power fields. Each bar represents the mean ± s.e.m of positive cells in liver sections from three mice. ***p < 0.001. e IL-6
ablation in monocytes suppresses circulating inflammatory factors. Data are presented as mean ± s.e.m, n ≥ 6; **p < 0.01 and ***p < 0.001 between
two groups, respectively. Scale bar = 100 μm
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IL-6 was upregulated in the tumors of Mdr2−/−IL-6+/+ mice
We speculated that high concentrations of IL-6 secreted
by local macrophages were associated with a high rate of
tumorigenesis. Therefore, we next examined the levels of
IL-6 in liver homogenates. As expected, IL-6 was signifi-
cantly decreased in both the surrounding tissues and
tumor tissues in Mdr2−/−IL6−/− mice (Fig. 6a).
STAT3 is a target of IL-6. After stimulation by IL-6,
STAT3 is phosphorylated, translocates to the cell nu-
cleus, and then functions as a transcriptional activator to
regulate various genes in response to cell stimuli,
thereby playing key roles in many cellular processes,
such as cell growth and apoptosis. The IL-6/STAT3 cas-
cade plays a key role in the promotion of hepatocyte
proliferation, liver repair, and tumorigenesis by protect-
ing cells from apoptotic stimuli and enhancing cell-cycle
progression. Therefore, we next investigated the involve-
ment of STAT3 in the transduction of IL-6 signal cas-
cades. Immunoblotting for phospho-STAT3 showed that
phospho-STAT3 was down-regulated in Mdr2−/−IL6−/−
mice. At the same time, proteins downstream of STAT3,
including Bcl-XL, cyclin D1, and c-Myc, were robustly
increased in Mdr2−/−IL6+/+ mice and moderately in-
creased in Mdr2−/−IL6−/− mice (Fig. 6b, c).
Discussion
In this study, we found that IL-6 levels and monocyte
numbers were significantly higher in peripheral blood
samples from patients with HCC than in patients with-
out HCC. Additionally, IL-6 expression was related to
the tumor grade in patients with HCC and had moderate
predictive value in relation to HCC. In the monocyte-
selective IL-6-deficient mouse model, we found that
WT/IL6+/+ mice induced by CCl4 exhibited higher levels
of toxic liver injury, inflammatory infiltration, and sys-
temic inflammation. Using a spontaneous tumorigen-
esis model that closely imitated inflammatory tumors,
we found that Mdr2−/−IL6+/+ mice had higher IL-6
levels in tumors and higher rates of early spontaneous
liver cancer. Furthermore, analysis of the molecular
Fig. 4 Loss of IL-6 in monocytes decreases spontaneous liver damage in mdr2−/− mice. a Loss of IL-6 in monocytes improves hepatic histology
and inhibits the infiltration of macrophages (scale bar = 50 μm). b IL-6 ablation in monocytes suppresses circulating inflammatory factors
in mdr2−/− mice. Data are presented as mean ± s.e.m, n ≥ 6; ***p < 0.001
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mechanisms showed the activation of STAT3 and its
downstream anti-apoptotic and pro-proliferation genes
in the Mdr2−/−IL6+/+ mice.
The inflammatory reaction is a complex double-edged
biological response in which leukocytes are critical and
the number of leukocytes often reflects the severity of
inflammation in patients. Based on the peripheral blood
data in our study, we determined that patients with
HCC had higher leukocyte counts than patients without
HCC, consistent with a report by Jian-Shong et al. [30].
In complete blood cell counts, leukocytes mainly include
neutrophils (≈62 %), lymphocytes (≈30 %), and mono-
cytes (≈5.3 %). Normally, IL-6 is not secreted by neutro-
phils, but promotes the release of neutrophils from BM.
Although IL-6 is mainly produced by macrophages and
lymphocytes, lymphocytes did not show any significant
differences between patients with or without HCC. In
addition, in humans, about 80 % of the total fixed mac-
rophages in the body are located in the liver. Taken to-
gether, these findings together and our current findings
suggested that the occurrence and development of HCC
may be related to the level of IL-6 secreted by macro-
phages and that a high level of IL-6 in turn promotes an
increase in the number of leukocytes. However, the spe-
cific mechanisms mediating these effects are still not
clear. Accordingly, based on the central role played by
IL-6 in the occurrence and development of HCC, we de-
veloped an appropriate mouse model to comprehen-
sively elucidate the gradual pathological changes in the
liver that occurred over time.
In previous studies, in order to decrease IL-6 levels in
the liver, researchers often used GdCl3 to deplete macro-
phages. However, many studies have demonstrated that
GdCl3, as a specific activator of calcium-sensing recep-
tors (CaSRs), does not just deplete KCs but also has a
wide range of other effects [31]. GdCl3 can suppress a
broad range of macrophage-related cell markers and
cytokines, including TNF-α, IL-6, and IL-1B [32, 33]. At
the same time, GdCl3 can reduce the levels of peroxi-
somal protein (PXP), CYP311, cytochrome P450, and
many functional mRNAs [34–37]. Systemic knockout of
IL-6 in mice has improved our understanding of the role
of IL-6 in hepatic pathophysiology to a greater degree
than GdCl3. However, systemic loss of IL-6 often leads
to spontaneous liver impairment and damaged regener-
ation [38]. Therefore, we cannot investigate the role of
IL-6 in the development of liver cancer using this trans-
genic model. Gp130 as a part of a receptor complex on
the cell surface, is crucial for all IL-6 family members
because they use this receptor for signal transduction
[25]. Although conditional knockout of gp130 using a
Cre/LoxP system successfully prevents embryonic lethal-
ity and specifically targets in nonparenchymal liver cells
or hepatocytes, gp130 knockout is not sufficient to
explain the role of monocytes in the pathogenesis of
liver diseases. Therefore, to overcome these challenges,
we constructed a mouse model in which the BM was de-
pleted by irradiation and then reconstituted using BM
from an IL-6-deficient mouse donor. In this model, IL-6
was disrupted in all nucleated cells derived from the
Fig. 5 Loss of IL-6 in monocytes decreases spontaneous liver cancer in mdr2−/− mice. a The gross view of spontaneous liver cancer in mice. b
The mean ratio of the LW/BW between mice with different bone marrow transplantation. Data are presented as mean ± s.e.m, n≥ 6; ***p < 0.001.
c Greatly less infiltrated macrophages in tumor tissue of Mdr2−/− & IL6−/−mice. Scale bar = 50 μm
Kong et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:131 Page 8 of 11
BM, including monocytes, dendritic cells, neutrophils,
and macrophages.
IL-6 is an essential activator for controlling the hepatic
AP response. Kovalovich et al. found that IL-6−/− mice de-
velop more severe liver fibrosis after CCl4 treatment [38].
In contrast, the WT/IL6+/+ mice induced by CCl4 treat-
ment in our study showed severe liver damage, whereas
liver histology in WT/IL6−/− mice was fairly well main-
tained, with moderately increased hepatic indexes. One
possible explanation of these observations is that
monocyte-selective IL-6-deficient mice may be less influ-
enced by other factors compared with traditional IL-6−/−
mice and may result in more targeted outcomes. Based on
the above study, TAM-derived IL-6 can expand the in-
flammatory response, leading to liver damage rather than
protective effects. IL-6 level is also consistently increased
in patients with chronic inflammatory response [39, 40]
and this is consistent with our clinical observations
(Fig. 1e). Coincidently, HCC is thought to be driven by in-
flammation. Many experiments in mice have shown that
nonspecific significant inhibition of hepatocyte prolifera-
tion in IL-6-deficient mice and the lack of IL-6 contributes
to the increase in mortality [23]. Moreover, IL-6 treatment
may be a therapeutic option for management of liver
Fig. 6 Loss of IL-6 in monocytes suppresses tumor growth signaling in mdr2−/− mice. a The transcription levels of IL-6 mRNA in tumor and non-tumor
tissues. b-c Immunoblotting of proteins involved in IL-6 signaling pathway. GAPDH and histone H3 were used as loading control of cytoplasmic protein
and nuclear protein, respectively. The levels of the indicated proteins are expressed as ratios to their loading control. Each bar represents the mean ±
s.e.m from ≥3 independent experiments. *p < 0.05
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damage by promoting hepatocyte proliferation [24]. Inter-
estingly, the outcomes in our study were not completely
consistent with these previously established protective
effects. In order to mimic inflammatory tumors, we chose
Mdr2−/− mice as a spontaneous tumorigenesis model [41].
In our study, we found that Mdr2−/−IL-6+/+ mice had a
higher rate of spontaneous liver cancer and larger tumors.
Therefore, we concluded that TAM-derived IL-6 may
contribute to the occurrence and development of HCC ra-
ther than only promoting hepatocyte proliferation.
Molecule-targeted therapy as a new approach based on
the study of HCC carcinogenic mechanisms may lead to
the improvement of treatment options for patients with
advanced HCC. After the development of the 2011
Barcelona Clinic Liver Cancer (BCLC) staging system,
only one drug (the multikinase inhibitor sorafenib) has
been approved for patients diagnosed with BCLC stage C
HCC (accounted for 40 % of patients with HCC) [42]. Al-
though molecular-targeted therapy is very important for
moderate to advanced HCC, few effective drugs have been
developed. Therefore, novel therapies are urgently needed.
IL-6 has a key role in carcinogen-driven liver cancer de-
velopment, promotes cancer cell proliferation, and inhibits
the apoptosis of cancer cells through the activation of
STAT3 [43–45, 17]. STAT3 activation induced by IL-6 via
JAK has been implicated in colitis-associated colon cancer
[46]. In our study, we focused on the IL-6/JAK/STAT3
pathway in the carcinogenesis of HCC. The levels of
phospho-STAT3 as a target of IL-6 were dramatically de-
creased in Mdr2−/−IL6−/− mice, and proteins downstream
of STAT3, including Bcl-XL, cyclin D1, and c-Myc, were
robustly increased in Mdr2−/−IL6+/+ mice. These findings
suggested that IL-6 may promote tumor development by
activating STAT3 and subsequently activating downstream
STAT3 target genes, including the anti-apoptotic gene en-
coding Bcl-XL and the cell cycle promoting genes encod-
ing cyclin-D1 and c-Myc. Our findings regarding the
molecular mechanisms of IL-6 are consistent with above
reports and may provide stronger evidence for the devel-
opment of molecular-targeted therapy.
Conclusions
In summary, TAM-derived IL-6 was highly correlated with
the occurrence and development of HCC. Using a
monocyte-selective IL-6-deficient mouse model of spon-
taneous inflammatory tumorigenesis, our findings directly
demonstrated that the increased TAM-derived IL-6 had
an amplifying effect on the inflammation response, and
further promoted the occurrence and development of
HCC. IL-6 played a vital role in carcinogenesis and this
deserves the attention from physicians. This information
may facilitate the development of novel strategies for the
early prevention and treatment for patients with HCC by
targeting the IL-6 system.
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